Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.

Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.

Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]

PMID:
31796517
2.

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF.

J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28.

PMID:
31657982
3.

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.

Li H, Whitney J, Bera K, Gilmore H, Thorat MA, Badve S, Madabhushi A.

Breast Cancer Res. 2019 Oct 17;21(1):114. doi: 10.1186/s13058-019-1200-6.

4.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr.

JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print]

PMID:
31566680
5.

Ductal carcinoma in situ of breast: update 2019.

Badve SS, Gökmen-Polar Y.

Pathology. 2019 Oct;51(6):563-569. doi: 10.1016/j.pathol.2019.07.005. Epub 2019 Aug 28. Review.

PMID:
31472981
6.

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.

Hancock BA, Chen YH, Solzak JP, Ahmad MN, Wedge DC, Brinza D, Scafe C, Veitch J, Gottimukkala R, Short W, Atale RV, Ivan M, Badve SS, Schneider BP, Lu X, Miller KD, Radovich M.

Breast Cancer Res. 2019 Aug 5;21(1):87. doi: 10.1186/s13058-019-1171-7.

7.

Commentary on: Risk factors of second surgery for adjacent segment disease following anterior cervical discectomy and fusion: A 16-year cohort study.

Kavadi N, Badve S.

Int J Surg. 2019 Sep;69:165. doi: 10.1016/j.ijsu.2019.07.010. Epub 2019 Jul 16. No abstract available.

PMID:
31323343
8.

Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, Jardine MJ, Sood MM, Garg AX, Palmer SC, Mark PB, Wheeler DC, Jha V, Freedman B, Johnson DW, Perkovic V, Badve SV.

Ann Intern Med. 2019 Aug 6;171(3):181-189. doi: 10.7326/M19-0087. Epub 2019 Jul 16.

PMID:
31307056
9.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

10.

Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.

Yeung WG, Toussaint ND, Badve SV.

J Am Soc Nephrol. 2019 Jun;30(6):909-910. doi: 10.1681/ASN.2019040333. Epub 2019 May 13. No abstract available.

PMID:
31085680
11.

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Aug;75(2):225-235. doi: 10.1111/his.13880. Epub 2019 Jul 8.

PMID:
31017314
12.

TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters.

Badve SS, Gökmen-Polar Y.

J Natl Cancer Inst. 2019 Nov 1;111(11):1118-1119. doi: 10.1093/jnci/djz052. No abstract available.

PMID:
30989234
13.

Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues.

Chen Y, Shen Q, White SL, Gokmen-Polar Y, Badve S, Goodman LJ.

Sci Rep. 2019 Apr 4;9(1):5624. doi: 10.1038/s41598-019-41957-w.

14.

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.

Viecelli AK, Polkinghorne KR, Pascoe EM, Paul-Brent PA, Hawley CM, Badve SV, Cass A, Hooi LS, Kerr PG, Mori TA, Ong LM, Voss D, Johnson DW, Irish AB; Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group.

PLoS One. 2019 Mar 26;14(3):e0213274. doi: 10.1371/journal.pone.0213274. eCollection 2019.

15.

The Mobi-C® cervical disc and other devices for two-level disc replacement: overview of its safety and efficacy.

Badve SA, Kurra S, Nunley PD, Lavelle WF.

Expert Rev Med Devices. 2019 Apr;16(4):307-315. doi: 10.1080/17434440.2019.1593137. Epub 2019 Mar 25. Review.

PMID:
30907183
16.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden GGVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Lawrence Wickerham D, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL.

J Natl Cancer Inst. 2019 Mar 19. pii: djz032. doi: 10.1093/jnci/djz032. [Epub ahead of print]

PMID:
30888406
17.

Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.

Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee.

BMJ Open. 2019 Feb 21;9(2):e024382. doi: 10.1136/bmjopen-2018-024382.

18.

Recent evidence for direct oral anticoagulants in chronic kidney disease.

Ha JT, Badve SV, Jun M.

Curr Opin Nephrol Hypertens. 2019 May;28(3):251-261. doi: 10.1097/MNH.0000000000000493.

PMID:
30789840
19.

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.

Gökmen-Polar Y, Neelamraju Y, Goswami CP, Gu Y, Gu X, Nallamothu G, Vieth E, Janga SC, Ryan M, Badve SS.

EMBO Rep. 2019 Feb;20(2). pii: e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.

PMID:
30665944
20.

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C.

JAMA Oncol. 2019 Jul 1;5(7):1036-1042. doi: 10.1001/jamaoncol.2018.6269.

21.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S.

J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.

PMID:
30650045
22.

Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies.

Boudville N, Ullah S, Clayton P, Sud K, Borlace M, Badve SV, Chakera A, Johnson DW.

Nephrol Dial Transplant. 2019 Jun 1;34(6):1035-1044. doi: 10.1093/ndt/gfy340.

PMID:
30561719
23.

EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Breast. 2019 Feb;43:74-80. doi: 10.1016/j.breast.2018.11.006. Epub 2018 Nov 17.

PMID:
30502641
24.

Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?

Tiku A, Badve SV, Johnson DW.

Am J Kidney Dis. 2018 Dec;72(6):776-778. doi: 10.1053/j.ajkd.2018.07.022. No abstract available.

PMID:
30470297
25.

Biocompatible dialysis fluids for peritoneal dialysis.

Htay H, Johnson DW, Wiggins KJ, Badve SV, Craig JC, Strippoli GF, Cho Y.

Cochrane Database Syst Rev. 2018 Oct 26;10:CD007554. doi: 10.1002/14651858.CD007554.pub3.

26.

Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.

Gökmen-Polar Y, True JD, Vieth E, Gu Y, Gu X, Qi GD, Mosley AL, Badve SS.

PLoS One. 2018 Oct 2;13(10):e0204658. doi: 10.1371/journal.pone.0204658. eCollection 2018.

27.

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2018 Sep 24;9:CD011798. doi: 10.1002/14651858.CD011798.pub2. Review.

28.

EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Clin Breast Cancer. 2019 Feb;19(1):17-26.e8. doi: 10.1016/j.clbc.2018.07.011. Epub 2018 Jul 17.

PMID:
30097312
29.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C; International Immuno-Oncology Biomarker Working Group.

Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157. doi: 10.1016/j.semcancer.2018.07.001. Epub 2018 Jul 7. Review.

PMID:
29990622
30.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

31.

Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process?

Priemer DS, Davidson DD, Loehrer PJ, Badve SS.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):661-664. doi: 10.1093/jnen/nly041.

PMID:
29850899
32.

The Relationship Between Body Mass Index and Organism-Specific Peritonitis.

Jegatheesan D, Johnson DW, Cho Y, Pascoe EM, Darssan D, Htay H, Hawley C, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP, Nadeau-Fredette AC.

Perit Dial Int. 2018 May-Jun;38(3):206-214. doi: 10.3747/pdi.2017.00188.

PMID:
29848600
33.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.

Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.

34.

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC; Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ.

Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

35.

Outcomes of Acinetobacter Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis.

Htay H, Cho Y, Pascoe EM, Hawley C, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP, Johnson DW.

Perit Dial Int. 2018 Jul-Aug;38(4):257-265. doi: 10.3747/pdi.2017.00199. Epub 2018 Feb 7.

PMID:
29437143
36.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ.

Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31.

37.

Review of long-term outcomes of disc arthroplasty for symptomatic single level cervical degenerative disc disease.

Badve SA, Nunley PD, Kurra S, Lavelle WF.

Expert Rev Med Devices. 2018 Mar;15(3):205-217. doi: 10.1080/17434440.2018.1433533. Epub 2018 Feb 5.

PMID:
29378457
38.

Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).

Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vilayur E, Rangan GK.

BMJ Open. 2018 Jan 21;8(1):e018794. doi: 10.1136/bmjopen-2017-018794. Erratum in: BMJ Open. 2018 Aug 5;8(8):e018794corr1.

39.

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE.

Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12.

40.

Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry.

Htay H, Cho Y, Pascoe EM, Darssan D, Nadeau-Fredette AC, Hawley C, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP, Johnson DW.

Am J Kidney Dis. 2018 Jun;71(6):814-821. doi: 10.1053/j.ajkd.2017.10.017. Epub 2017 Dec 28.

PMID:
29289475
41.

Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study.

See EJ, Johnson DW, Hawley CM, Pascoe EM, Badve SV, Boudville N, Clayton PA, Sud K, Polkinghorne KR, Borlace M, Cho Y.

Am J Kidney Dis. 2018 Aug;72(2):188-197. doi: 10.1053/j.ajkd.2017.10.019. Epub 2017 Dec 23.

PMID:
29277508
42.

Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.

Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, Hawley CM, Isbel NM, Marshall MR, Pascoe EM, Pedagogos E, Pilmore HL, Snelling P, Stanton T, Tan KS, Tonkin AM, Vergara LA, Ierino FL.

Kidney Blood Press Res. 2017;42(6):1033-1044. doi: 10.1159/000485589. Epub 2017 Dec 4.

43.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
44.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS.

J Thorac Oncol. 2018 Mar;13(3):436-446. doi: 10.1016/j.jtho.2017.11.118. Epub 2017 Nov 27.

45.

MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.

Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R, Gularte-Merida R, Forbes AN, Khurana E, Mariani O, Badve S, Vincent-Salomon A, Norton L, Reis-Filho JS, Weigelt B.

J Pathol. 2018 Feb;244(2):143-150. doi: 10.1002/path.5006. Epub 2017 Dec 28.

46.

Single-cell heterogeneity in ductal carcinoma in situ of breast.

Gerdes MJ, Gökmen-Polar Y, Sui Y, Pang AS, LaPlante N, Harris AL, Tan PH, Ginty F, Badve SS.

Mod Pathol. 2018 Mar;31(3):406-417. doi: 10.1038/modpathol.2017.143. Epub 2017 Nov 17.

47.

Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study.

Lim WH, Badve SV, Wong G.

Oncotarget. 2017 Sep 8;8(44):77771-77782. doi: 10.18632/oncotarget.20781. eCollection 2017 Sep 29.

48.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

49.

EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS.

See EJ, Johnson DW, Hawley CM, Pascoe EM, Darssan D, Clayton PA, Borlace M, Badve SV, Sud K, Boudville NC, Cho Y.

Perit Dial Int. 2017 Sep 28. pii: pdi.2017.00029. doi: 10.3747/pdi.2017.00029. [Epub ahead of print]

PMID:
28970365
50.

Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya.

Sawe RT, Mining SK, Ofulla AV, Patel K, Guyah B, Chumba D, Prosperi JR, Kerper M, Shi Z, Sandoval-Cooper M, Taylor K, Badve S, Stack MS, Littlepage LE.

Trop Med Health. 2017 Aug 4;45:19. doi: 10.1186/s41182-017-0059-4. eCollection 2017.

Supplemental Content

Support Center